Zacks Investment Research upgraded shares of aTyr Pharma (NASDAQ:LIFE) from a hold rating to a buy rating in a research note released on Friday. They currently have $3.25 price target on the biotechnology company’s stock.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Other equities research analysts have also issued reports about the stock. ValuEngine lowered shares of aTyr Pharma from a sell rating to a strong sell rating in a report on Friday, December 1st. JPMorgan Chase & Co. lowered shares of aTyr Pharma from a neutral rating to an underweight rating in a report on Wednesday, February 14th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $4.56.
A number of institutional investors and hedge funds have recently bought and sold shares of LIFE. Artal Group S.A. grew its holdings in aTyr Pharma by 100.0% during the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after acquiring an additional 250,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after acquiring an additional 164,500 shares during the last quarter. Victory Capital Management Inc. bought a new stake in aTyr Pharma during the 3rd quarter worth approximately $455,000. Deutsche Bank AG bought a new stake in aTyr Pharma during the 4th quarter worth approximately $199,000. Finally, Dimensional Fund Advisors LP grew its holdings in aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 25,676 shares during the last quarter. 52.62% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3258724/atyr-pharma-life-upgraded-by-zacks-investment-research-to-buy.html.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.